Continuing the Conversation: A Review of Targeted Therapies for Early-Stage Breast Cancer | PTCE Pharmacy Connect

Educational Objectives

• Outline the place in therapy for targeted therapies based on patient-specific factors and subtype of early-stage breast cancer
• Recognize methods to improve patient treatment selection while mitigating toxicities in patients with early-stage breast cancer

Faculty:

Allison R. Butts, PharmD, BCOP

Pharmacist Manager, Oncology

Breast Oncology Clinical Pharmacy Specialist

Acute Care Pharmacy Services

UK HealthCare- Markey Cancer

Lexington, Kentucky

 

Director, PGY2 Oncology Residency Program

UK HealthCare

Lexington, Kentucky

Allison R. Butts, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:

Consultant: AstraZeneca; BeyondSpring (one-time advisory boards)

Moderator:

Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth

OncoHealth

Laura R. Bobolts, PharmD, BCOP, has no financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-239-H01-P. The activity is available for CE credit through May 31, 2024.

This activity is supported by independent medical educational grants from AstraZeneca; Merck & Co., Inc.; Puma Biotechnology Inc., and Lilly.